Pharma Mar, S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHMMF research report →
Companywww.pharmamar.com
Pharma Mar, S. A. , a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally.
- CEO
- Jose Maria Fernandez Sousa-Faro
- IPO
- 2016
- Employees
- 500
- HQ
- Madrid, ES
Price Chart
Valuation
- Market Cap
- $1.84B
- P/E
- 21.60
- P/S
- 7.75
- P/B
- 6.96
- EV/EBITDA
- 25.23
- Div Yield
- 0.79%
Profitability
- Gross Margin
- 92.66%
- Op Margin
- 26.12%
- Net Margin
- 35.70%
- ROE
- 35.74%
- ROIC
- 19.05%
Growth & Income
- Revenue
- $221.31M · 26.57%
- Net Income
- $74.96M · 186.92%
- EPS
- $4.36 · 192.62%
- Op Income
- $40.26M
- FCF YoY
- 561.19%
Performance & Tape
- 52W High
- $110.40
- 52W Low
- $80.91
- 50D MA
- $87.88
- 200D MA
- $92.53
- Beta
- 0.37
- Avg Volume
- 29
Get TickerSpark's AI analysis on PHMMF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PHMMF Coverage
We haven't published any research on PHMMF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PHMMF Report →